for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

3,744.00JPY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2,894.50

 - 

4,562.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,744.00
Open
--
Volume
--
3M AVG Volume
79.05
Today's High
--
Today's Low
--
52 Week High
4,562.00
52 Week Low
2,894.50
Shares Out (MIL)
1,563.10
Market Cap (MIL)
5,901,997.00
Forward P/E
45.63
Dividend (Yield %)
4.81

Next Event

Q2 2021 Takeda Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Elektrofi, Takeda Enter Agreement On Elektrofi's Formulation Tech

Takeda Pharmaceutical- Phase 2 Elektra Study Of Soticlestat Meets Primary Endpoint

Takeda & Novavax Announce Collaboration For Novavax' COVID-19 Vaccine Candidate In Japan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Industry

Major Drugs

Contact Info

4F, 2-1-1, Nihombashihon-cho

CHUO-KU, TKY

103-8668

Japan

+81.3.32782111

https://www.takeda.com/

Executive Leadership

Masahiro Sakane

Independent Chairman of the Executive Board

Christophe Weber

President, Chief Executive Officer, Representative Director

Constantine Saroukos

Chief Financial Officer, Director

Masato Iwasaki

President of Japan Pharma Business Unit, President of Subsidiary, Director

Andrew S. Plump

President of Research & Development, Director

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

1.8K

2019

2.1K

2020

3.3K

2021(E)

3.3K
EPS (JPY)

2018

239.350

2019

113.500

2020

28.410

2021(E)

78.798
Price To Earnings (TTM)
48.95
Price To Sales (TTM)
1.82
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
8.83
Total Debt To Equity (MRQ)
108.28
LT Debt To Equity (MRQ)
95.89
Return on Investment (TTM)
1.08
Return on Equity (TTM)
0.92

Latest News

Latest News

Takeda-led COVID-19 plasma product to begin trial this month

An experimental COVID-19 therapy using blood plasma, developed by Japan's Takeda Pharmaceutical Co and its partners, is scheduled to begin a late-stage clinical trial after initial delays.

Fed Circuit revives Takeda patent case against Genentech

A federal appeals court on Thursday revived a lawsuit filed by a Takeda Pharmaceutical Co unit alleging one of its patents was infringed by the Genentech hemophilia drug Hemlibra, reversing one of its own judges who was sitting in a lower court.

Takeda to sell Japan consumer health unit valued at $2.3 billion to Blackstone

Takeda Pharmaceutical Co said on Monday it would sell its Japanese consumer healthcare business to U.S. buyout fund Blackstone Group, as it aims to focus on developing drugs for unmet medical needs and rare diseases.

Takeda to sell Japanese consumer health unit to Blackstone for $2.3 bln

Takeda Pharmaceutical Co has agreed to sell its Japanese consumer healthcare business to U.S. investment fund Blackstone Group for 242 billion yen ($2.3 billion), Japan's largest drugmaker said on Monday.

Takeda preparing to sell Japan consumer health unit to Blackstone: Kyodo

Japan's Takeda Pharmaceutical Co Ltd <4502.T> is making final arrangements to sell its domestic over-the-counter (OTC) business to U.S. investment fund Blackstone Group Inc <BX.N>, Kyodo News reported on Wednesday.

Takeda to make Novavax's COVID-19 vaccine candidate in Japan

Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.

BRIEF-Takeda & Novavax Announce Collaboration For Novavax' COVID-19 Vaccine Candidate In Japan

* NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN

Takeda Pharma raises profit forecast as it focuses on core drug business

Japan's Takeda Pharmaceutical Co <4502.T> on Friday raised its full-year profit forecast as it refocuses on its core prescription drug businesses following its $59 billion takeover of Shire Plc last year.

Takeda Pharmaceutical to cut sales jobs in Japan, sources say

Takeda Pharmaceutical Co <4502.T> is looking to cut sales jobs in Japan in its latest restructuring effort, as it overhauls domestic business following its $59 billion purchase of Shire Plc, sources familiar with the company's plans said.

Takeda Pharmaceutical to cut sales jobs in Japan - sources

Takeda Pharmaceutical Co is looking to cut sales jobs in Japan in its latest restructuring effort, as it overhauls domestic business following its $59 billion purchase of Shire Plc, sources familiar with the company's plans said.

Breakingviews - Takeda feeling uncomfortable Shire side effects

Takeda Pharmaceutical is showing signs of recovery after a mega-merger, but shareholders keep feeling the pain. Some 18 months after completing a $62 billion takeover of Irish rival Shire, the Japanese drugmaker may sell another business to further pare debt. Promised cost...

BRIEF-Takeda Partners With Twist Bioscience To Expand Biologics Discovery Capabilities

* TAKEDA PARTNERS WITH TWIST BIOSCIENCE TO EXPAND BIOLOGICS DISCOVERY CAPABILITIES Source text for Eikon: Further company coverage:

BRIEF-Takeda Pharmaceutical Co - Files For Offering Of 4-Part, Senior Notes Of Up To $7 Billion

* TAKEDA PHARMACEUTICAL CO - FILES FOR OFFERING OF 4-PART, SENIOR NOTES OF UP TO $7 BILLION - SEC FILING Source text for Eikon: [ID: https://bit.ly/2YJG363] Further company coverage:

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

Takeda Pharmaceutical Co Ltd <4502.T> said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

BRIEF-Takeda Files Prelim Prospectus Supplement Related To USD Denominated Four-Part Senior Notes Offering

* TAKEDA PHARMACEUTICAL - FILES PRELIM PROSPECTUS SUPPLEMENT RELATED TO USD DENOMINATED FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED Source text (https://bit.ly/3fXtUQM) Further company coverage:

BRIEF-Takeda Files Prelim Prospectus Supplement Related To Four-Part Senior Notes Offering Size Not Disclosed

* TAKEDA PHARMACEUTICAL SAYS IT FILES PRELIM PROSPECTUS SUPPLEMENT RELATED TO FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text (https://bit.ly/2Nzc6zb) Further company coverage:

BRIEF-Takeda Pharmaceutical Files For Debt Shelf; Size Not Disclosed - SEC Filing

* TAKEDA PHARMACEUTICAL CO LTD FILES FOR DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: https://bit.ly/31ddjV9 Further company coverage:

Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources

Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's <4502.T> consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.

BRIEF-Neurocrine Biosciences, Takeda Announce Collaboration To Develop Potential Therapies For Psychiatric Disorders

* NEUROCRINE BIOSCIENCES AND TAKEDA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE POTENTIAL THERAPIES FOR PSYCHIATRIC DISORDERS

Japan's Takeda to sell some Asia-focused drugs to Celltrion for $278 million

Takeda Pharmaceutical Co Ltd <4502.T> has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea's Celltrion Inc <068270.KS> for $278 million, it said on Thursday

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up